Pharming (PHAR) Cash & Equivalents (2018 - 2026)
Pharming's (PHAR) quarterly Cash & Equivalents came in at $158.3 million in Q2 2026, up 71.87% YoY from $92.1 million in Q2 2025, and up 202.18% on a QoQ basis from $52.4 million in Q1 2026.
Pharming (PHAR) Cash & Equivalents (2018 - 2026) Analysis & Trends
Pharming (PHAR) has 9 years of Cash & Equivalents data on file, last reported at $158.3 million in Q2 2026.
- Quarterly Cash & Equivalents rose 71.87% year-over-year to $158.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $158.3 million (up 71.87% YoY) and the FY2025 annual result came in at $145.3 million, up 9587.0% from the prior year.
- Cash & Equivalents grew to $158.3 million in Q2 2026, from $52.4 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $207.3 million in Q4 2022 to a low of $1.5 million in Q4 2024.
- A 5-year average of $123.7 million and a median of $138.8 million in 2025 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 106934.94% in 2022, down 99.91% in 2022.
- Tracing PHAR's Cash & Equivalents over 5 years: stood at $207.3 million in 2022, then slumped by 70.22% to $61.7 million in 2023, then slumped by 97.57% to $1.5 million in 2024, then jumped by 9587.0% to $145.3 million in 2025, then advanced by 8.93% to $158.3 million in 2026.
- The last three Cash & Equivalents figures came in at $158.3 million (Q2 2026), $52.4 million (Q1 2026), and $145.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 158.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 158.28 Mn |
| Mar 31, 2026 | 52.38 Mn |
| Dec 31, 2025 | 145.31 Mn |
| Sep 30, 2025 | 132.37 Mn |
| Jun 30, 2025 | 92.09 Mn |
| Mar 31, 2025 | 60.09 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 60.66 Mn |
| Jun 30, 2024 | 47.14 Mn |
| Mar 31, 2024 | 51.89 Mn |
| Dec 31, 2023 | 61.74 Mn |
| Sep 30, 2023 | 207.34 Mn |
| Jun 30, 2023 | 192.37 Mn |
| Mar 31, 2023 | 184.78 Mn |
| Dec 31, 2022 | 207.34 Mn |
| Sep 30, 2022 | 191.92 Mn |
| Jun 30, 2022 | 189.96 Mn |
| Mar 31, 2022 | 189.67 Mn |
| Dec 31, 2021 | 193,714.32 |
| Sep 30, 2021 | 183.32 Mn |